ArticleHaematologica2023
Comprehensive molecular and clinical characterization of
4 registry-linked trialsOpen access · goldAbstract read
In one paragraph
Article in Haematologica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 64 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed, 1 pooled it
23.2field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A phase iii study in children with untreated acute myelogenous leukemia (aml) or myelodysplastic syndrome (mds)
Treatment of Newly Diagnosed Childhood Acute Myeloid Leukemia (AML) Using Intensive MRC-Based Therapy and Gemtuzumab Ozogamicin (GMTZ): A COG Pilot Study
A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults
A Phase III Randomized Trial for Patients With De Novo AML Using Bortezomib and Sorafenib (NSC# 681239, NSC# 724772) for Patients With High Allelic Ratio FLT3/ITD
Who cites it
64 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.
- Molecular Landscape of Acute Myeloid Leukemia in Pediatric Patient-Age-Related Correlations: A Systematic Review.International journal of molecular sciences · 2025Pooled it
- The nuclear pore complex as a spatial organizing hub for high-risk DNA lesions.Nucleus (Austin, Tex.) · 2026Review
- Uncovering essential RNA components of fusion oncoprotein condensates using bicon-seq.The EMBO journal · 2026Article
- Nucleoporins in Cancer: Functional Roles and Therapeutic Opportunities.Cancer discovery · 2026Article
- Myeloid blast phase of chronic myeloid leukemia with co-occurring t(11;12)(p15;q13)/Haematologica · 2026Article
- Immunophenotypic, Cytogenetic, and Molecular Characterization of NUP98-Rearranged Pediatric Myeloid Neoplasms.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2026Article
- A New Paradigm for Pediatric AML: Improving the Pipeline for Treatments Targeting Cytogenetic and Molecular Alterations.Cancers · 2026Review
- [Clinical analysis of nine pediatric cases of acute myeloid leukemia with NUP98 rearrangement].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026Article
- Article
- DNA Methylation of Pharmacologic and Leukemia-Related Genes Predicts Clinical Outcomes in Pediatric Acute Myeloid Leukemia.Cancers · 2026Article
- Developmental timing distinguishes pediatric and adult cancers through retention and rewiring mechanisms.Nature communications · 2026Review
- Comprehensive mutational profiling and clinical outcome of adult acute myeloid leukemia patients with NUP98 rearrangement.Leukemia · 2026Article
- Conception-calibrated male pediatric tumor mitotic clocks.Communications biology · 2026Article
- Durable remission despite transplantation with active disease in therapy-related NUP98::TOP1-rearranged acute myeloid leukemia.Annals of hematology · 2026Article
- [Prognostic impact of WT1 mutations in patients with acute myeloid leukemia].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026Article
- [Prognostic analysis of NUP98 rearrangement in patients with pediatric acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026Article
- Metabolic regulation of tumor-associated macrophage function and immunotherapy in cancer.Cancer biology & medicine · 2026Review
- Preferential formation of NUP98-KDM5A condensates at specific H3K4me3-rich loci drives leukemogenic gene expression.bioRxiv : the preprint server for biology · 2026Article
- Ontogeny Dictates Oncogenic Potential, Lineage Hierarchy, and Therapy Response in Pediatric Leukemia.Cancer discovery · 2026Article
- NUP98 rearrangements in adult AML patients: evaluation of clinical implications and identification of novel fusion partners.Leukemia · 2026Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
37 authors at 20 institutions in 8 countries.
Eline J M BertrumsPrincess Maxima Center for Pediatric Oncology, Utrecht, the Netherlands; Department of Pediatric Oncology/Hematology, Erasmus Medical Center - Sophia Children's Hospital, Rotterdam, the Netherlands; Oncode Institute, Utrecht. e.j.m.bertrums@prinsesmaximacentrum.nl.
Jenny L SmithFred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, WA.
Lauren HarmonDepartment of Epigenetics, Van Andel Institute, Grand Rapids, MI.
Rhonda E RiesFred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, WA.
Yi-Cheng J WangDepartment of Translational Genomics, University of Southern California, Los Angeles, CA, USA; Children's Oncology Group, Monrovia, CA.
Todd A AlonzoDepartment of Translational Genomics, University of Southern California, Los Angeles, CA, USA; Children's Oncology Group, Monrovia, CA.
Andrew J MenssenHematologics, Inc, Seattle, WA.
Karen M ChisholmDepartment of Laboratories, Seattle Children's Hospital, Seattle, WA.
Amanda R LeontiFred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, WA.
Katherine TarlockFred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, WA, USA; Division of Hematology and Oncology, Seattle Children's Hospital, Seattle, WA.
Fabiana OstronoffIntermountain Blood and Marrow Transplant and Acute Leukemia Program, Intermountain Healthcare, Salt Lake City, UT.
Era L Pogosova-AgadjanyanFred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, WA.
Gertjan J L KaspersPrincess Maxima Center for Pediatric Oncology, Utrecht, the Netherlands; Emma Children's Hospital, Amsterdam UMC, Vrije Universiteit Amsterdam, Pediatric Oncology, The Netherlands; Dutch Childhood Oncology Group.
Henrik HasleDepartment of Pediatrics, Aarhus University Hospital, Aarhus, Denmark.
Michael DworzakChildren's Cancer Research Institute, Medical University of Vienna, Vienna, Austria; St. Anna Kinderspital, Department of Pediatrics, Medical University of Vienna, Vienna.
Christiane WalterDepartment of Pediatric Hematology and Oncology, University Hospital Essen, Essen.
Nora MuhleggerChildren's Cancer Research Institute, Medical University of Vienna, Vienna.
Cristina MorerioLaboratory of Human Genetics, IRCCS Istituto Giannina Gaslini, Genoa.
Laura PardoHematologics, Inc, Seattle, WA.
Betsy HirschDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, TN.
Susana RaimondiDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, TN.
Todd M CooperDivision of Hematology and Oncology, Seattle Children's Hospital, Seattle, WA.
Richard AplencDivision of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA.
Alan S GamisDivision of Hematology/Oncology, Children's Mercy Kansas City, Kansas City, MO.
Edward A KolbNemours Alfred I. duPont Hospital for Children, Wilmington, DE.
Jason E FarrarArkansas Children's Research Institute and Department of Pediatrics, Hematology/Oncology Section, Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, AR.
Derek StirewaltFred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, WA.
Xiaotu MaComputational Biology Department, St. Jude Children's Research Hospital, Memphis, TN.
Tim I ShawComputational Biology Department, St. Jude Children's Research Hospital, Memphis, TN.
Scott N FurlanFred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, WA.
Lisa Eidenschink BrodersenHematologics, Inc, Seattle, WA.
Michael R LokenHematologics, Inc, Seattle, WA.
Marry M Van den Heuvel-EibrinkPrincess Maxima Center for Pediatric Oncology, Utrecht, the Netherlands; Utrecht University, Utrecht.
C Michel ZwaanPrincess Maxima Center for Pediatric Oncology, Utrecht, the Netherlands; Department of Pediatric Oncology/Hematology, Erasmus Medical Center - Sophia Children's Hospital, Rotterdam, the Netherlands; Dutch Childhood Oncology Group.
Timothy J TricheDepartment of Epigenetics, Van Andel Institute, Grand Rapids, MI, USA; Department of Translational Genomics, University of Southern California, Los Angeles, CA, USA; Department of Pediatrics, Michigan State University College of Human Medicine, Grand Rapids, MI.
Bianca F GoemansPrincess Maxima Center for Pediatric Oncology, Utrecht.
Soheil MeshinchiFred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, WA, USA; Children's Oncology Group, Monrovia, CA, USA; Division of Hematology and Oncology, Seattle Children's Hospital, Seattle, WA. smeshinc@fredhutch.org.
Fred Hutch Cancer Center · USSt. Jude Children's Research Hospital · USSeattle Children's Hospital · USUniversity of Southern California · USAarhus University Hospital · DKAlfred I. duPont Hospital for Children · USArkansas Children's Hospital · USChildren's Hospital of Philadelphia · USChildren's Mercy Hospital · USChildren's Oncology Group · CHEmma Kinderziekenhuis · NLEssen University Hospital · DEIntermountain Healthcare · USIstituto Giannina Gaslini · ITMedical University of Vienna · ATOncode Institute · NLPrincess Máxima Center · NLSt Anna Children's Hospital · ATStichting Kinderoncologie Nederland · NLUtrecht University · NL
Funding
NCTN BIQSFP ANBL1531 (NRT)U10CA180886 · NCI · PUBLIC HEALTH INSTITUTE · PI Douglas S. Hawkins · 2014 to 2026
$390.6MSWOG Network Group Operations Center of the NCTNU10CA180888 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI PRIMO N. LARA · 2014 to 2026
$152.1MCOG SDMC - Statistics CoreU10CA180899 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI TODD A ALONZO · 2014 to 2026
$132.8MSWOG Statistics & Data Management Center complex - extension supplement for GY06U10CA180819 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Catherine M. Tangen · 2014 to 2026
$115.2MSWOG U24 Funding for 2026-2027U24CA196175 · NCI · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI James Michael Rae, Nilsa Del Carmen Ramirez Milan · 2015 to 2026
$37.6MNovel Biomarkers to Risk-Stratify AML Patients with NPM1^Pos/FLT3-IT^Neg GenotypeR01CA190661 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI STIREWALT, DEREK L · 2016 to 2020
$2.7MDiscovery and Optimization of AML Prognostic BiomarkersR01CA160872 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI STIREWALT, DEREK L · 2012 to 2016
$2.5MThe roles of genetics, hormones, and gender in sexually dimorphic immune responseR01AI171984 · NIAID · VAN ANDEL RESEARCH INSTITUTE · PI KRAWCZYK, CONNIE, PROKOP, JEREMY WILLIAM · 2022 to 2024
$1.4MNCI NIH HHS R01 CA160872NCI NIH HHS R01 CA190661NCI NIH HHS U10 CA180819NCI NIH HHS U10 CA180886NCI NIH HHS U10 CA180888NCI NIH HHS U10 CA180899NCI NIH HHS U24 CA196175NIAID NIH HHS R01 AI171984
Abstract
NUP98 fusions comprise a family of rare recurrent alterations in AML, associated with adverse outcomes. In order to define the underlying biology and clinical implications of this family of fusions, we performed comprehensive transcriptome, epigenome, and immunophenotypic profiling of 2,235 children and young adults with AML and identified 160 NUP98 rearrangements (7.2%), including 108 NUP98-NSD1 (4.8%), 32 NUP98-KDM5A (1.4%) and 20 NUP98-X cases (0.9%) with 13 different fusion partners. Fusion partners defined disease characteristics and biology; patients with NUP98-NSD1 or NUP98-KDM5A had distinct immunophenotypic, transcriptomic, and epigenomic profiles. Unlike the two most prevalent NUP98 fusions, NUP98-X variants are typically not cryptic. Furthermore, NUP98-X cases are associated with WT1 mutations, and have epigenomic profiles that resemble either NUP98-NSD1 or NUP98-KDM5A. Cooperating FLT3-ITD and WT1 mutations define NUP98-NSD1, and chromosome 13 aberrations are highly enriched in NUP98-KDM5A. Importantly, we demonstrate that NUP98 fusions portend dismal overall survival, with the noteworthy exception of patients bearing abnormal chromosome 13 (clinicaltrials gov. Identifiers: NCT00002798, NCT00070174, NCT00372593, NCT01371981).
Indexed as
Leukemia, Myeloid, AcuteChildGene Expression ProfilingHumansMutationNuclear Pore Complex ProteinsRetinoblastoma-Binding Protein 2Young AdultKDM5A protein, humannuclear pore complex protein 98Nuclear Pore Complex ProteinsRetinoblastoma-Binding Protein 2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
NCT00002798ClinicalTrials.gov
NCT00070174ClinicalTrials.gov
NCT00372593ClinicalTrials.gov
NCT01371981ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.